node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
AKR1A1 | GUSB | ENSP00000312606 | ENSP00000302728 | aldo-keto reductase family 1, member A1 (aldehyde reductase); Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotic [...] | glucuronidase, beta; Plays an important role in the degradation of dermatan and keratan sulfates | 0.906 |
AKR1A1 | KL | ENSP00000312606 | ENSP00000369442 | aldo-keto reductase family 1, member A1 (aldehyde reductase); Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotic [...] | klotho; May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By similarity). Essential factor for the specific interaction between FGF23 and FGFR1 (By similarity) | 0.900 |
AKR1A1 | MIOX | ENSP00000312606 | ENSP00000216075 | aldo-keto reductase family 1, member A1 (aldehyde reductase); Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotic [...] | myo-inositol oxygenase | 0.808 |
CDIPT | IMPA1 | ENSP00000219789 | ENSP00000408526 | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | 0.920 |
CDIPT | IMPA2 | ENSP00000219789 | ENSP00000269159 | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | 0.905 |
CDIPT | IMPAD1 | ENSP00000219789 | ENSP00000262644 | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | inositol monophosphatase domain containing 1; May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3’,5’-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation (By similarity) | 0.900 |
CDIPT | MIOX | ENSP00000219789 | ENSP00000216075 | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | myo-inositol oxygenase | 0.909 |
GUSB | AKR1A1 | ENSP00000302728 | ENSP00000312606 | glucuronidase, beta; Plays an important role in the degradation of dermatan and keratan sulfates | aldo-keto reductase family 1, member A1 (aldehyde reductase); Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4- nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D- glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotic [...] | 0.906 |
GUSB | KL | ENSP00000302728 | ENSP00000369442 | glucuronidase, beta; Plays an important role in the degradation of dermatan and keratan sulfates | klotho; May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By similarity). Essential factor for the specific interaction between FGF23 and FGFR1 (By similarity) | 0.850 |
GUSB | MIOX | ENSP00000302728 | ENSP00000216075 | glucuronidase, beta; Plays an important role in the degradation of dermatan and keratan sulfates | myo-inositol oxygenase | 0.800 |
IMPA1 | CDIPT | ENSP00000408526 | ENSP00000219789 | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | 0.920 |
IMPA1 | IMPA2 | ENSP00000408526 | ENSP00000269159 | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | 0.961 |
IMPA1 | IMPAD1 | ENSP00000408526 | ENSP00000262644 | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | inositol monophosphatase domain containing 1; May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3’,5’-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation (By similarity) | 0.937 |
IMPA1 | MIOX | ENSP00000408526 | ENSP00000216075 | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | myo-inositol oxygenase | 0.952 |
IMPA2 | CDIPT | ENSP00000269159 | ENSP00000219789 | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | 0.905 |
IMPA2 | IMPA1 | ENSP00000269159 | ENSP00000408526 | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | 0.961 |
IMPA2 | IMPAD1 | ENSP00000269159 | ENSP00000262644 | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | inositol monophosphatase domain containing 1; May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3’,5’-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation (By similarity) | 0.939 |
IMPA2 | MIOX | ENSP00000269159 | ENSP00000216075 | inositol(myo)-1(or 4)-monophosphatase 2; Can use myo-inositol monophosphates, scylloinositol 1,4- diphosphate, glucose-1-phosphate, beta-glycerophosphate, and 2’- AMP as substrates. Has been implicated as the pharmacological target for lithium Li(+) action in brain | myo-inositol oxygenase | 0.947 |
IMPAD1 | CDIPT | ENSP00000262644 | ENSP00000219789 | inositol monophosphatase domain containing 1; May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3’,5’-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation (By similarity) | CDP-diacylglycerol--inositol 3-phosphatidyltransferase; Catalyzes the biosynthesis of phosphatidylinositol (PtdIns) as well as PtdIns-inositol exchange reaction. May thus act to reduce an excessive cellular PtdIns content. The exchange activity is due to the reverse reaction of PtdIns synthase and is dependent on CMP, which is tightly bound to the enzyme | 0.900 |
IMPAD1 | IMPA1 | ENSP00000262644 | ENSP00000408526 | inositol monophosphatase domain containing 1; May play a role in the formation of skeletal elements derived through endochondral ossification, possibly by clearing adenosine 3’,5’-bisphosphate produced by Golgi sulfotransferases during glycosaminoglycan sulfation (By similarity) | inositol(myo)-1(or 4)-monophosphatase 1; Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol- phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1- phosphate, beta-glycerophosphate, and 2’-AMP as substrates | 0.937 |